4-(1H-咪唑-1-基)苯甲酸 | 17616-04-5

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-(1H-咪唑-1-基)苯甲酸
• 中文别名: 4-(1-咪唑基)苯甲酸
• 英文名称: 4-(1H-imidazol-1-yl)benzoic acid
• 英文别名: 4-(imidazol-1-yl)benzoic acid；4-(1H-imidazolyl)benzoic acid；4-imidazol-1-ylbenzoic acid
• CAS: 17616-04-5
• 化学式: C₁₀H₈N₂O₂
• mdl: MFCD00586645
• 分子量: 188.186
• InChiKey: LFIDZIWWYNTQOQ-UHFFFAOYSA-N

物化性质

• 熔点：
  305 °C (dec.)(lit.)
• 沸点：
  403.6±28.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  按规定使用，这种物质不会分解，并且能够避免氧化。

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2933290090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	4-(1h-imidazol-1-yl)benzoic acid 90+% Material Safety Data Sheet
Synonym:
CAS:	17616-04-5

Section 1 - Chemical Product MSDS Name:4-(1h-imidazol-1-yl)benzoic acid 90+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
17616-04-5	4-(1H-Imidazol-1-yl)benzoic acid	90+%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 17616-04-5: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 309 - 311 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H8N2O2
Molecular Weight: 188.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 17616-04-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(1H-Imidazol-1-yl)benzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 17616-04-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 17616-04-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 17616-04-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(1H-咪唑-1-基)苯甲酸 在 CYP₁₉₉A₄ from Rhodopseudomonas palustris HaA₂ 作用下， 反应 4.0h， 生成 4-[[2-(formylamino)acetyl]amino]benzoic acid
  参考文献：
  名称：

  成为或不成为抑制剂：唑类与细胞色素 P450 酶的相互作用和氧化作用的比较

  摘要：

  血红素单加氧酶的细胞色素 P450 (CYP) 超家族参与自然界中一系列重要的化学生物转化。含唑分子已被开发为药物，可与这些酶的血红素中心结合，抑制其功能。添加这些抑制剂后 CYP 酶的光谱用于评估分子如何结合。在这里，我们使用来自沼泽红假单胞菌HaA2 的细菌 CYP199A4 酶来比较咪唑基和三唑基抑制剂如何与铁和亚铁血红素结合。 4-(咪唑-1-基)苯甲酸引起三价铁酶中 Soret 波长 (424 nm) 的红移，同时 δ 和 α 带强度分别增加和减少。 4-(1 H -1,2,4-三唑-1-基)苯甲酸以低 10 倍的亲和力与 CYP199A4 结合，并在 Soret 带中诱导较小的红移。具有这两种抑制剂的 CYP199A4 的晶体结构证实，光谱中的这些差异是由于咪唑基配体与三价铁的配位所致，但三唑基抑制剂与三价铁水配体相互作用，而不是取代。与 4-(1 H -1,2,4-三唑-1-基)苯甲酸结合的

  DOI：

  10.1021/acs.inorgchem.1c02786
• 作为产物：
  描述：

  1-(4-甲醛基苯基)咪唑 在 1-羟基环己基苯基甲酮 、 sodium hydroxide 作用下， 以 乙二醇二甲醚 为溶剂， 以91%的产率得到4-(1H-咪唑-1-基)苯甲酸
  参考文献：
  名称：

  通过氢原子转移将伯醇和醛氧化成羧酸

  摘要：

  伯醇和伯醛氧化成相应的羧酸是有机合成中的基本反应。在本文中，我们报告了一种用于氧化伯醇和醛的新化学选择性工艺。这种无金属反应具有新的氧化剂、易于操作的程序、高分离产率以及即使在易受攻击的仲醇和叔丁烷亚磺酰胺存在下也具有良好至优异的官能团耐受性的特点。

  DOI：

  10.1021/acs.orglett.1c02188
• 作为试剂：
  描述：

  2,2'-联吡啶 、 dysprosium(III) nitrate hexahydrate 在 4-(1H-咪唑-1-基)苯甲酸 作用下， 以 乙腈 为溶剂， 反应 120.33h， 以68%的产率得到[Dy(bipy) (HNO₃)_3(NO3^-)]₂
  参考文献：
  名称：

  基于具有双峰发射和Eu 3+掺杂的Dy 3+材料的双官能配体构建的镧系元素MOF ：白色发射和颜色调整†

  摘要：

  基于氮杂双环配体，已经通过水（溶剂）热反应合成了四种3D超分子镧系元素配合物，通常配制成[Dy（bipy）（NO 3）3 ] 2（1·Dy），[Dy（bipy）2（NO 3）3 ]（2·Dy），[Dy 2（bpdc）3（DMF）（H 2 O）] 2 ·（DMF）10（H 2 O）（3·Dy）和[Eu 4（bpdc）6（CH 3 NH 2）3（DMSO）（H 2 O）]（4·Eu）（Bipy = 2,2'-联吡啶; H 2 bpdc = 2,2'-联吡啶-5,5'-二羧酸，DMF = N，N-二甲基甲酰胺），结构上由单晶X表征射线衍射，红外光谱，元素分析和粉末X射线衍射（PXRD）。在配合物1·Dy中，沿a / c，b，c轴分别存在三种氢键，分别为C2-H2A⋯O6，C4-H4A⋯O4和C8-H8A⋯O8 。他们将1·Dy复合物连接到3D 6连接的pcu超分子网络中。2·Dy通过两种氢键连接

  DOI：

  10.1039/c6ra14896d

文献信息

• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
• Sulfonamide derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06359134B1

  公开（公告）日：2002-03-19

  The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1 is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.

  本发明提供了一种化合物，该化合物特异性地抑制FXa，口服给药有效，并且用作预防或治疗由血栓或梗死引起的疾病的药物是安全的。本发明的化合物是哌嗪酮的公式： 其中R1是可选地取代的烃基或可选地取代的杂环基；环A是除了被公式：的基团取代的之外的可选地取代的二价含氮杂环基： 和公式的基团： Y是可选地取代的二价烃基或可选地取代的二价杂环基；X是直接键或可选地取代的亚烷基链；Z是（1）与可选地取代的烃基取代的氨基，（2）可选地取代的亚氨基或（3）可选地取代的含氮杂环基；当X是直接键并且Z是可选地取代的6-成员含氮芳香杂环基时，Y是可选地取代的二价烃基或可选地取代的二价不饱和杂环基；或其盐。
• [EN] PYRIDINYL CARBAMATES AS HORMONE-SENSITIVE LIPASE INHIBITORS<br/>[FR] CARBAMATES DE PYRIDINYLE UTILISES EN TANT QU'INHIBITEURS DE LA LIPASE HORMONO-SENSIBLE
  申请人：NOVO NORDISK AS

  公开号：WO2004111031A1

  公开（公告）日：2004-12-23

  Novel substituted pyridinyl carbamates of general formula (I):, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to hormone sensitive lipase. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which modulation of the activity of hormone sensitive lipase is beneficial.

  具有一般公式(I)的新型取代吡啶基氨基甲酸酯，包含它们的药物组合物以及在治疗和/或预防与激素敏感脂肪酶相关的疾病和障碍中的用途。更具体地说，这些化合物对于治疗和/或预防调节激素敏感脂肪酶活性有益的疾病和障碍非常有用。
• Identification of a New Class of Nonpeptidic Inhibitors of Cruzain
  作者：Katrien Brak、Patricia S. Doyle、James H. McKerrow、Jonathan A. Ellman

  DOI：10.1021/ja710254m

  日期：2008.5.1

  inhibitors. The previously unexplored beta-chloro vinyl sulfone pharmacophore provided mechanistic insight that led to the development of potent irreversible acyl- and aryl-oxymethyl ketone cruzain inhibitors. For these inhibitors, potency did not solely depend on leaving group p K a, with 2,3,5,6-tetrafluorophenoxymethyl ketone 54 identified as one of the most potent inhibitors with a second-order inactivation

  Cruzain 是克氏锥虫的主要半胱氨酸蛋白酶，它是南美锥虫病的病原体，是开发新化疗的有希望的靶点。为了开发有效的 cruzain 非肽抑制剂，使用底物活性筛选 (SAS) 方法筛选最初设计用于靶向同源人蛋白酶组织蛋白酶 S 的蛋白酶底物库。接下来使用基于结构的设计来进一步改进底物通过在 cruzain 的 S3 口袋中引入额外的结合相互作用来提高切割效率。然后通过引入基于半胱氨​​酸蛋白酶机制的药效团将优化的底物转化为抑制剂。抑制剂 38 被确定是可逆的，即使它掺入了乙烯基砜药效团，该药效团已被充分证明可以对肽抑制剂产生不可逆的 cruzain 抑制作用。先前未探索的 β-氯乙烯基砜药效团提供了导致开发有效的不可逆酰基和芳基氧甲基酮 cruzain 抑制剂的机理洞察力。对于这些抑制剂，效力不仅仅取决于离去基团 p K a，2,3,5,6-四氟苯氧基甲基酮 54 被鉴定为最有效的抑制剂之一，其二级失活常数为
• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102303A1

  公开（公告）日：2020-04-02

  Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. Wherein R 1 , R 2 , R 2a , R 3 , R 3a , R 4 , and R 4a are defined herein.

  化合物的结构式（I）和结构式（II），含有它们的药物组合物，制备它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、紊乱和病况的方法，例如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、躁郁症）、癌症和眼部疾病相关的方法。 其中R1、R2、R2a、R3、R3a、R4和R4a在此处定义。